
|Videos|December 11, 2020
Biomarkers Used to Detect Secondary Progressive MS Needs Improvement for the Care of Patients
Author(s)Briana Contreras
Thomas P. Leist, MD, PhD, says doctors working with patients diagnosed with SPMS don't necessarily have prognostic biomarkers to detect SPMS. The best prognostic biomarkers they have currently are MRI and potentially neurofilament light. He adds their techniques need to improve in order to harness the full benefit of potentially individualizing care to the most optimal fashion in a given patient.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
3
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5



























